In this context, to support and broaden the exploration of ERK1/2-targeted therapeutic strategies in the management of iCCA, we have outlined the most recent advancements from both experimental models and preclinical studies involving small-molecule inhibitors aimed at attenuating the hyperactivation of this signaling cascade. This evidence concerns the gene MAPK3 and infantile convulsions and choreoathetosis.